ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Company profile
Ticker
ARDX
Exchange
Website
CEO
Michael Raab
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NTERYX INC
SEC CIK
ARDX stock data
Latest filings (excl ownership)
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
5 Mar 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
22 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Departure of Directors or Certain Officers
13 Nov 23
10-Q
2023 Q3
Quarterly report
31 Oct 23
8-K
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
31 Oct 23
8-K
Entry into a Material Definitive Agreement
18 Oct 23
8-K
Other Events
17 Oct 23
Transcripts
ARDX
Earnings call transcript
2023 Q3
31 Oct 23
ARDX
Earnings call transcript
2023 Q2
2 Aug 23
ARDX
Earnings call transcript
2023 Q1
4 May 23
ARDX
Earnings call transcript
2022 Q4
2 Mar 23
ARDX
Earnings call transcript
2022 Q3
6 Nov 22
ARDX
Earnings call transcript
2022 Q2
7 Aug 22
ARDX
Earnings call transcript
2022 Q1
6 May 22
ARDX
Earnings call transcript
2021 Q4
1 Mar 22
ARDX
Earnings call transcript
2018 Q2
7 Aug 18
Latest ownership filings
4
MICHAEL RAAB
17 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
MICHAEL RAAB
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Mike Kelliher
27 Mar 24
3
Mike Kelliher
27 Mar 24
4
Robert Blanks
22 Mar 24
4
ELIZABETH A GRAMMER
22 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
David P. Rosenbaum
28 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.77 mm | 33.77 mm | 33.77 mm | 33.77 mm | 33.77 mm | 33.77 mm |
Cash burn (monthly) | (no burn) | 2.32 mm | (no burn) | 2.03 mm | 7.16 mm | 5.56 mm |
Cash used (since last report) | n/a | 15.90 mm | n/a | 13.89 mm | 49.00 mm | 38.07 mm |
Cash remaining | n/a | 17.87 mm | n/a | 19.88 mm | -15.23 mm | -4.30 mm |
Runway (months of cash) | n/a | 7.7 | n/a | 9.8 | -2.1 | -0.8 |
Institutional ownership, Q2 2023
61.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 146 |
Opened positions | 42 |
Closed positions | 30 |
Increased positions | 45 |
Reduced positions | 36 |
13F shares | Current |
---|---|
Total value | 424.02 bn |
Total shares | 142.96 mm |
Total puts | 1.38 mm |
Total calls | 534.70 k |
Total put/call ratio | 2.6 |
Largest owners | Shares | Value |
---|---|---|
STT State Street | 22.44 mm | $76.06 bn |
JHG Janus Henderson | 21.83 mm | $73.94 bn |
BLK Blackrock | 14.03 mm | $47.56 bn |
New Enterprise Associates 12, Limited Partnership | 13.63 mm | $94.34 mm |
Vanguard | 11.47 mm | $38.88 bn |
Millennium Management | 6.98 mm | $23.65 bn |
Geode Capital Management | 4.22 mm | $14.29 bn |
Flynn James E | 2.56 mm | $16.57 mm |
Intrinsic Edge Capital Management | 2.45 mm | $8.32 bn |
BAC Bank Of America | 2.42 mm | $8.21 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Michael Raab | Common Stock | Sell | Dispose S | No | Yes | 7.0565 | 7,500 | 52.92 k | 1,310,933 |
1 Apr 24 | Michael Raab | Common Stock | Sell | Dispose S | No | Yes | 7.31 | 1,518 | 11.10 k | 1,318,433 |
25 Mar 24 | Mike Kelliher | Common Stock | Grant | Acquire A | No | No | 0 | 160,000 | 0.00 | 160,000 |
25 Mar 24 | Mike Kelliher | Stock Option Common Stock | Grant | Acquire A | No | No | 7.7 | 205,000 | 1.58 mm | 205,000 |
20 Mar 24 | Grammer Elizabeth A | Common Stock | Sell | Dispose S | No | Yes | 7.7323 | 86,000 | 664.98 k | 312,993 |
News
Wedbush Maintains Outperform on Ardelyx, Raises Price Target to $14
17 Apr 24
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
5 Apr 24
A Closer Look at 6 Analyst Recommendations For Ardelyx
5 Apr 24
Leerink Partners Initiates Coverage On Ardelyx with Outperform Rating, Announces Price Target of $14
5 Apr 24
What's Going On With Ardelyx Stock After Earnings?
23 Feb 24
Press releases
Ardelyx, Inc. Reports Employment Inducement Grants
12 Mar 24
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
28 Feb 24
Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?
23 Feb 24
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
22 Feb 24
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
1 Feb 24